首页> 外文期刊>Drug Design, Development and Therapy >Gamma scintigraphic study of the hydrodynamically balanced matrix tablets of Metformin HCl in rabbits
【24h】

Gamma scintigraphic study of the hydrodynamically balanced matrix tablets of Metformin HCl in rabbits

机译:盐酸二甲双胍水动力平衡基质片剂在兔体内的伽玛闪烁显像研究

获取原文
           

摘要

Abstract: The purpose of this study is to evaluate the in vitro and in vivo performance of gastro-retentive matrix tablets having Metformin HCl as model drug and combination of natural polymers. A total of 16 formulations were prepared by a wet granulation method using xanthan, tamarind seed powder, tamarind kernel powder and salep as the gel-forming agents and sodium bicarbonate as a gas-forming agent. All the formulations were evaluated for compendial and non-compendial tests and in vitro study was carried out on a USP-II dissolution apparatus at a paddle speed of 50 rpm. MOX2 formulation, composed of salep and xanthan in the ratio of 4:1 with 96.9% release, was considered as the optimum formulation with more than 90% release in 12 hours and short floating lag time. In vivo study was carried out using gamma scintigraphy in New Zealand White rabbits, optimized formulation was incorporated with 10 mg of 153Sm for labeling MOX2 formulation. The radioactive samarium oxide was used as the marker to trace transit of the tablets in the gastrointestinal tract. The in vivo data also supported retention of MOX2 formulation in the gastric region for 12 hours and were different from the control formulation without a gas and gel forming agent. It was concluded that the prepared floating gastro-retentive matrix tablets had a sustained-release effect in vitro and in vivo, gamma scintigraphy played an important role in locating the oral transit and the drug-release pattern.
机译:摘要:本研究的目的是评估以盐酸二甲双胍为模型药物和天然聚合物组合的胃滞留基质片剂的体外和体内性能。使用黄原胶,罗望子种子粉末,罗望子仁粉末和salep作为凝胶形成剂,以及碳酸氢钠作为气体形成剂,通过湿法制粒制备总共16种制剂。评估所有制剂的药典和非药典测试,并在USP-II溶出仪上以50 rpm的桨叶速度进行体外研究。由Salep和黄原胶以4:1的比例组成,释放率为96.9%的MOX2制剂被认为是最佳的制剂,在12小时内释放率超过90%,漂浮滞后时间短。在新西兰白兔中使用伽玛闪烁显像技术进行了体内研究,将优化的配方与10 mg 153Sm掺入以标记MOX2配方。放射性sa氧化物用作标记物以追踪片剂在胃肠道中的转运。体内数据还支持MOX2制剂在胃区域中保留12小时,并且与没有气体和凝胶形成剂的对照制剂不同。结论是,制备的漂浮性胃滞留基质片剂在体内和体外具有缓释作用,γ闪烁显像在确定口服转运和药物释放方式中起着重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号